Aktis bags $72M in Novartis, BMS-backed series A to unlock power of radiopharmaceuticals ntaylor Thu, 03/18/2021 - 08:52.: Aktis Oncology has raised a $72 million series A round to develop radiopharmaceutical treatments for solid tumors. The MPM Capital-founded biotech received investment from Novartis and Bristol Myers Squibb. Nuclear medicine began decades ago with the use of beta emitters such as radioactive iodine. Such drugs achieved some success but failed in microscopic and disseminated cancers, potentially because of their relatively long particle path length and low linear energy transfer.